crisprtx.comCrawled Nov 7, 2026
Sickle cell disease is an inherited blood disorder caused by mutations in the hemoglobin gene, leading to crescent-shaped red blood cells.
CRISPR Therapeutics is focused on the development and commercialization of novel therapies to treat hemoglobinopathies, cancer, diabetes, and other diseases.
Dr. Emmanuelle Charpentier co-invented CRISPR/Cas9 gene editing, which revolutionized biomedical research and enabled medical breakthroughs.
Exa-cel, a CRISPR/Cas9 gene-edited therapy developed with Vertex Pharmaceuticals, treats sickle cell disease and transfusion-dependent beta thalassemia by editing hematopoietic stem cells.
Chuck, a former Vice President of Business Operations at the National Fire Protection Association, approaches challenges by analyzing details and forming plans.
Keturah, diagnosed with cutaneous T cell lymphoma, now consults, advocates, and speaks to support others with similar experiences.
- Aims to develop an immune-evasive stem cell therapy as a potentially curative treatment for diabetes -
CRISPR Therapeutics builds a research and development center with teams focused on advancing gene-based medicines.
Mr. Kasinger serves as CRISPR Therapeutics’ General Counsel and Secretary, overseeing legal, governance, compliance, and intellectual property matters.
The company is led by experienced management, a board of directors, and scientific founders with backgrounds in biotechnology and pharmaceuticals.
Megan Wherry Menner brings human resources experience from Merck KGaA, including roles at Merck Millipore Life Science and EMD Serono.
Naimish Patel, M.D., serves as CRISPR Therapeutics’ Chief Medical Officer after leading immunology and inflammation programs at Sanofi.
CRISPR Therapeutics focuses on developing gene-based medicines for serious diseases.
CRISPR Therapeutics partners with biopharma companies, academic centers, and universities to support its therapeutic programs.
CRISPR Therapeutics develops gene-based medicines to treat serious diseases.
CTX310, an investigational in vivo CRISPR therapy, lowered cholesterol and triglycerides through one year in early trials. Results presented at ESC Congress 2026 and published in The New England Journal of Medicine.
